Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Bromodomain-containing protein 2 is a protein that is encoded by the BRD2 gene. It plays a role in spermatogenesis. It plays a role in the regulation of transcription, probably by chromatin remodeling and also plays a role in nucleosome assembly. It regulates transcription of the CCND1 gene.
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Oncology, Dermatology and Immunology which include indications Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Lymphoma, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Myelofibrosis, Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Ovarian Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Small-Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), Atopic Dermatitis (Atopic Eczema), B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Colon Cancer, Colorectal Cancer, Dermatitis (Eczema), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Follicular Lymphoma, Inflammation, Leukemia, Lung Cancer, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Non-Small Cell Lung Cancer, Pancreatic Cancer, Peritoneal Cancer, Primary Mediastinal B-Cell Lymphoma, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma) and Unspecified B-Cell Lymphomas.
The latest report Bromodomain Containing Protein 2 - Drugs In Development, 2022, outlays comprehensive information on the Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Bromodomain-containing protein 2 is a protein that is encoded by the BRD2 gene. It plays a role in spermatogenesis. It plays a role in the regulation of transcription, probably by chromatin remodeling and also plays a role in nucleosome assembly. It regulates transcription of the CCND1 gene.
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Oncology, Dermatology and Immunology which include indications Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Lymphoma, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Myelofibrosis, Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Ovarian Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Small-Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), Atopic Dermatitis (Atopic Eczema), B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Colon Cancer, Colorectal Cancer, Dermatitis (Eczema), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Follicular Lymphoma, Inflammation, Leukemia, Lung Cancer, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Non-Small Cell Lung Cancer, Pancreatic Cancer, Peritoneal Cancer, Primary Mediastinal B-Cell Lymphoma, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma) and Unspecified B-Cell Lymphomas.
The latest report Bromodomain Containing Protein 2 - Drugs In Development, 2022, outlays comprehensive information on the Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)
- The report reviews Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Overview
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Companies Involved in Therapeutics Development
AbbVie Inc
Amgen Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Constellation Pharmaceuticals Inc
Ningbo Wenda Pharmaceutical Technology Co Ltd
VYNE Therapeutics Inc
Zenith Epigenetics Ltd
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Drug Profiles
ABBV-744 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BI-894999 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CC-95775 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NHWD-870 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NUE-19796 - Drug Profile
Product Description
Mechanism Of Action
History of Events
pelabresib - Drug Profile
Product Description
Mechanism Of Action
History of Events
QCA-570 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VYN-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VYN-202 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ZEN-3694 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Dormant Products
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Discontinued Products
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Product Development Milestones
Featured News & Press Releases
Mar 07, 2022: VYNE reports positive preclinical data for lead BET Inhibitor, VYN201, in human skin model of vitiligo
Feb 22, 2022: Zenith Epigenetics announces dosing of first cancer patient with a combination of ZEN-3694 + Bristol Myers Squibb’s immune checkpoint inhibitor OPDIVO
Dec 12, 2021: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
Nov 04, 2021: MorphoSys to present MANIFEST data from expanded hematology-oncology portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting
Nov 04, 2021: Lead BET inhibitor, VYN201, demonstrates improvement in reducing fibrotic tissue mass and overall skin repair outcomes in preclinical study
Oct 26, 2021: Lead BET inhibitor, VYN201, significantly reduces expression of several key pro-inflammatory cytokines in preclinical studies
Sep 21, 2021: Zenith Epigenetics and Newsoara announce initiation of a randomized phase 2b metastatic castration-resistant prostate cancer (mCRPC) study
Aug 17, 2021: Zenith Epigenetics announces a publication in the journal of Cancer Gene Therapy with compelling data for the treatment of ER-positive breast cancer patients
Jun 24, 2021: Zenith Epigenetics announces a publication highlighting the role of ZEN-3694 in overcoming resistance to therapies in metastatic castration-resistant prostate cancer
Jun 11, 2021: Constellation Pharmaceuticals provides an update from the ongoing MANIFEST study of Pelabresib
Jun 11, 2021: Constellation Pharmaceuticals provides an update from the Ongoing MANIFEST study of Pelabresib
Mar 15, 2021: Zenith Epigenetics announces dosing of first mCRPC patient with a combination of ZEN-3694 + Merck’s immune check point inhibitor KEYTRUDA
Jan 07, 2021: Constellation Pharmaceuticals appoints Brendan Delaney as Chief Commercial Officer
Dec 06, 2020: Constellation Pharmaceuticals provides update of MANIFEST study for CPI-0610 at ASH Meeting
Nov 23, 2020: Constellation Pharmaceuticals to host analyst / investor event to discuss update of MANIFEST clinical trial for CPI-0610 presented at ASH Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Overview
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Companies Involved in Therapeutics Development
AbbVie Inc
Amgen Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Constellation Pharmaceuticals Inc
Ningbo Wenda Pharmaceutical Technology Co Ltd
VYNE Therapeutics Inc
Zenith Epigenetics Ltd
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Drug Profiles
ABBV-744 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BI-894999 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CC-95775 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NHWD-870 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NUE-19796 - Drug Profile
Product Description
Mechanism Of Action
History of Events
pelabresib - Drug Profile
Product Description
Mechanism Of Action
History of Events
QCA-570 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VYN-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VYN-202 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ZEN-3694 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Dormant Products
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Discontinued Products
Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Product Development Milestones
Featured News & Press Releases
Mar 07, 2022: VYNE reports positive preclinical data for lead BET Inhibitor, VYN201, in human skin model of vitiligo
Feb 22, 2022: Zenith Epigenetics announces dosing of first cancer patient with a combination of ZEN-3694 + Bristol Myers Squibb’s immune checkpoint inhibitor OPDIVO
Dec 12, 2021: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
Nov 04, 2021: MorphoSys to present MANIFEST data from expanded hematology-oncology portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting
Nov 04, 2021: Lead BET inhibitor, VYN201, demonstrates improvement in reducing fibrotic tissue mass and overall skin repair outcomes in preclinical study
Oct 26, 2021: Lead BET inhibitor, VYN201, significantly reduces expression of several key pro-inflammatory cytokines in preclinical studies
Sep 21, 2021: Zenith Epigenetics and Newsoara announce initiation of a randomized phase 2b metastatic castration-resistant prostate cancer (mCRPC) study
Aug 17, 2021: Zenith Epigenetics announces a publication in the journal of Cancer Gene Therapy with compelling data for the treatment of ER-positive breast cancer patients
Jun 24, 2021: Zenith Epigenetics announces a publication highlighting the role of ZEN-3694 in overcoming resistance to therapies in metastatic castration-resistant prostate cancer
Jun 11, 2021: Constellation Pharmaceuticals provides an update from the ongoing MANIFEST study of Pelabresib
Jun 11, 2021: Constellation Pharmaceuticals provides an update from the Ongoing MANIFEST study of Pelabresib
Mar 15, 2021: Zenith Epigenetics announces dosing of first mCRPC patient with a combination of ZEN-3694 + Merck’s immune check point inhibitor KEYTRUDA
Jan 07, 2021: Constellation Pharmaceuticals appoints Brendan Delaney as Chief Commercial Officer
Dec 06, 2020: Constellation Pharmaceuticals provides update of MANIFEST study for CPI-0610 at ASH Meeting
Nov 23, 2020: Constellation Pharmaceuticals to host analyst / investor event to discuss update of MANIFEST clinical trial for CPI-0610 presented at ASH Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AbbVie Inc, 2022
Pipeline by Amgen Inc, 2022
Pipeline by Boehringer Ingelheim International GmbH, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Constellation Pharmaceuticals Inc, 2022
Pipeline by Ningbo Wenda Pharmaceutical Technology Co Ltd, 2022
Pipeline by VYNE Therapeutics Inc, 2022
Pipeline by Zenith Epigenetics Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AbbVie Inc, 2022
Pipeline by Amgen Inc, 2022
Pipeline by Boehringer Ingelheim International GmbH, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Constellation Pharmaceuticals Inc, 2022
Pipeline by Ningbo Wenda Pharmaceutical Technology Co Ltd, 2022
Pipeline by VYNE Therapeutics Inc, 2022
Pipeline by Zenith Epigenetics Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
